A rare disease in the United States is one that affects fewer than 200,000 people in the country. Congress established this definition in the Orphan Drug Act of 1983. Because pharma corporations were not interested in developing medicines for rare diseases, they became known as orphan diseases. The Orphan Drug Act established financial incentives for companies to discover new medicines for uncommon diseases. The definition of rare disease was required in order to determine which disorders would be eligible for the new incentive programmes. Certain cell types can be created in abnormally large quantities or in atypical forms when the usual process of blood cell growth and development breaks down. Blood malignancies and other blood problems arise as a result of this.
Title : Hereditary hemolytic anemias due to red blood cell membranopathies rheological and genetic approach
Joan Lluis Vives Corrons, Institute for Leukaemia Research Josep Carreras, Spain
Title : Histologic transformation of mantle zone lymphoma to diffuse large B-Cell lymphoma: A case report of disease relapse after Covid-19 infection
Lilija Bancevica, Riga Stradins University, Latvia
Title : Improving outcomes of curable lymphoma in resource constrained regions
Reena Nair, TATA Medical Centre, India
Title : Covid-19 and erythrocyte groups
Marina Nagervadze, Batumi Shota Rustaveli State University, Georgia
Title : Achieving 100% blood traceability compliance: A United Kingdom district hospital experience
Francis Ajeneye, Princess Alexandra Hospital NHS Trust, United Kingdom
Title : Role of erythrocytapheresis in sickle cell anemia crisis management: A tertiary care centre experience from Chhattisgarh state of central India
Neelesh Jain, Transfusion Medicine at Balco Medical Centre, India